Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease…Ongoing

A Randomized, Placebo controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease. (Prodromal AD)

This is an 18 month study in which subjects that screen and qualify will go onto the program taking the investigation medication by mouth once daily.